Two placebo-controlled trials presented at the 2026 AHA Scientific Sessions found semaglutide significantly improved cardiac structure, function, and pulmonary artery wedge pressure in patients with heart failure with preserved ejection fraction and obesity.
The recent failure of a Novartis experimental heart drug in a large trial has raised questions among cardiologists about the widely held idea that reducing levels of genetically set cholesterol improves cardiovascular outcomes.
Researchers led by Joris Deelen have created a personalized metabolic indicator that uses ten blood markers to provide a detailed snapshot of a patient's metabolism, aimed at promoting healthy aging and reversing the trend of chronic conditions affecting 60% of people over age 65.
Researchers at Baylor College of Medicine and University of Oxford found that blocking a specific molecular interaction between microRNA-31-5p and calcitonin receptor reduced atrial fibrosis and abnormal heart rhythms in mouse models and human cells, offering a potential RNA-based therapeutic strategy for atrial fibrillation.
Researchers led by Aitziber L. Cortajarena at CIC biomaGUNE have developed a new iron-based contrast agent for magnetic resonance imaging that can both diagnose and treat cardiac fibrosis. The agent was tested on three-dimensional models of human cardiac tissue using preclinical MRI scanners.
Abbott received FDA approval for its Amplatzer Paraclose PVL Occluder, the first transcatheter device designed to close paravalvular leaks around surgical replacement heart valves without requiring additional open-heart surgery.
Research conducted in Brazil by University of São Paulo scientists found that each additional day of heat wave exposure in São Paulo is associated with increased acute stroke risk in people aged 65 and older. The study defined a heat wave as at least two consecutive days with maximum temperatures of 33.1°C (92°F) or higher.
Researchers at the University of Utah have identified a backup energy system in the heart that uses the protein MCT1 to import lactate into mitochondria, where it is converted to pyruvate to sustain cardiac function when normal glucose pathways fail. The discovery, demonstrated in mouse hearts, shows this mechanism can prevent stress-induced heart failure.
An international research team led by Laura de Rooij at CeMM Research Center for Molecular Medicine has created the Human Aging Endothelial Cell Atlas, revealing how endothelial cells—the inner linings of blood vessels—change throughout a human lifespan. The atlas provides new insights into how blood vessels age from within.
Researchers at the University of Manchester and Manchester University NHS Foundation Trust have identified a previously hidden defect in the tiny blood vessels of women with preeclampsia, a dangerous pregnancy complication. The discovery, published in Circulation Research, could open the door to new treatments for the condition that threatens both mothers and babies.
A major trial published in JAMA shows that a simple adjustment to drugs given during operations for septic shock could prevent thousands of patients from suffering kidney damage. Scientists from the University of Southampton and Zhejiang University School of Medicine conducted the research.
China's drug regulator approved Bayer's blood thinner asundexian for stroke prevention, marking the first approval globally for this new class of anticoagulant. The approval followed a priority review and represents a significant boost for Bayer's pharmaceutical pipeline.
University of Exeter researchers have characterized the 'average' human genome for the first time, revealing that most people carry high genetic risk for around three of 28 common conditions, including diabetes, cardiovascular disease, and schizophrenia, though this does not mean they are destined to become ill.
A cross-sectional study of nearly 9,000 Canadian adults found that higher consumption of ultraprocessed foods was associated with silent vascular brain injury in middle-aged adults without cardiovascular disease, though no apparent effect on cognition was observed. The research also linked ultraprocessed food intake to greater body fat.
A new analysis published in Family Medicine and Community Health found that greater consumption of ultra-processed foods significantly increases the risk for multiple chronic diseases and death. The findings align with prior research connecting ultra-processed foods to adverse health outcomes including cancer, type 2 diabetes, and cardiovascular disease.
Novartis and Ionis's pelacarsen failed to protect heart health despite lowering Lp(a) levels in a large clinical trial, raising questions about the therapeutic approach and increasing pressure on Novartis's drug pipeline. Shares fell 3.3%.
Cytokinetics announced detailed late-stage trial results showing its drug aficamten significantly improved symptoms and exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy, a genetic heart condition with no approved treatments.
A new study shows that tirzepatide (Mounjaro), a GLP-1 receptor agonist drug, reduces heart attack risk by 33% when added to standard care for patients with both type 2 diabetes and existing heart disease. The findings come as worldwide sales of the drug doubled to £13.8 billion in the first half of 2026.
Mineralys Therapeutics presented new data at a major European medical conference showing their experimental pill significantly reduced blood pressure in patients with chronic kidney disease.
Cytokinetics announced its heart disease drug Myqorzo, already approved in one indication, succeeded in meeting twin efficacy goals in a Phase 3 trial for genetic heart disease, potentially boosting future sales.
Frequent, long, or early-day naps in older adults are linked to higher mortality risk and may signal underlying conditions like cardiovascular disease, neurodegeneration, or sleep disorders, suggesting daytime sleep patterns could serve as an early warning sign of declining health.